Pharmaceutical care issues encountered by post-menopausal osteoporotic women prescribed bisphosphonates

Journal of Clinical Pharmacy and Therapeutics

Volumn 37, Issue 5, 2012, Pages 536-543

  Lai, P S M ^a   Chua, S S ^a   Chan, S P ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

bisphosphonates; Malaysia; osteoporosis; pharmaceutical care issues; pharmacist intervention; post menopausal

Indexed keywords

ALENDRONIC ACID; RISEDRONIC ACID;

ABDOMINAL DISTENSION; ADULT; AGED; ARTICLE; ATTITUDE TO HEALTH; BONE DENSITY; CONTROLLED STUDY; COOPERATION; COUNSELING; DIARRHEA; DRUG WITHDRAWAL; ESOPHAGITIS; FEMALE; FEVER; FOLLOW UP; GASTRITIS; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INTERVIEW; LEG CRAMP; LETHARGY; MAJOR CLINICAL STUDY; MUSCULOSKELETAL PAIN; NAUSEA; PATIENT SATISFACTION; PHARMACEUTICAL CARE; POSTMENOPAUSE OSTEOPOROSIS; QUALITY OF LIFE; RASH;

ADULT; AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; ETIDRONIC ACID; FEMALE; FOLLOW-UP STUDIES; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INTERVENTION STUDIES; MALAYSIA; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT SATISFACTION; PHARMACEUTICAL SERVICES; QUALITY OF LIFE;

EID: 84865865333     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2012.01335.x     Document Type: Article

References (37)

1. Kanis J, Melton LJ,. The diagnosis of osteoporosis. J Bone Miner Res 1994; 9: 1137-1141. (Pubitemid 24985932)
2. International Osteoporosis Foundation. About osteoporosis (for health professionals): basic bone biology. International Osteoporosis Foundation; 2008. Available at: http://www.iofbonehealth.org/health-professionals/about- osteoporosis.html. (accessed 14 March 2008).
3. Davidson M,. Pharmacotherapeutics for osteoporosis prevention and treatment. J Midwifery Womens Health 2003; 48: 39-54.
4. Melton LJ 3rd,. The prevalence of osteoporosis: gender and racial comparison. Calcif Tissue Int 2001; 69: 179-181.
5. Lau EMC, Lee JK, Suriwongpaisal P, Saw SM, Das De S, Khir A, Sambrook P,. The incidence of hip fracture in four Asian countries: the Asian Osteoporosis Study (AOS). Osteoporos Int 2001; 12: 239-243. (Pubitemid 32288941)
6. Hepler CD, Strand LM,. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990; 47: 533-543. (Pubitemid 20138134)
7. Pols HAP, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporos Int 1999; 9: 461-468. (Pubitemid 29231740)
8. Blau EM, Gordon SJ, Benton LK, Weiss TW, Chen YT,. Establishment of an innovative clinic for postmenopausal women at high risk for fragility fracture. Drug Benefit Trends 2003; 15: 41-46.
9. Cerulli J, Zeolla MM,. Impact and feasibility of a community pharmacy bone mineral density screening and education program. J Am Pharm Assoc 2004; 44: 161-167.
10. Cuddihy MT, Amadio PC, Gabriel SE, Pankratz VS, Kurland RL, Melton LJ,. A prospective clinical practice intervention to improve osteoporosis management following distal forearm fracture. Osteoporos Int 2004; 15: 695-700. (Pubitemid 39222651)
11. Goode JV, Swiger K, Bluml BM,. Regional osteoporosis screening, referral, and monitoring program in community pharmacies: findings from project ImPACT: osteoporosis. J Am Pharm Assoc 2004; 44: 152-160.
12. Gray M, Rajaei-Dahkordi Z, Ewan M, Wysocki R,. Investigating the potential contribution of community pharmacists in identifying, understanding and meeting the bone health needs of patients in collaboration with GPs. Int J Pharm Pract, 2002; 10 (Suppl.): R34.
13. MacLaughlin EJ, MacLaughlin AA, Snella KA, Winston TS, Fike DS, Raehl CR,. Osteoporosis screening and education in community pharmacies using a team approach. Pharmacotherapy 2005; 25: 379-386. (Pubitemid 40300325)
14. Newman ED, Hanus P,. Improved bone health behavior using community pharmacists as educators-the geisinger health system community pharmacist osteoporosis education program. Dis Mana Heal Outcomes 2001; 9: 329-335. (Pubitemid 32538818)
15. Jaglal SB, Hawker G, Bansod V, et al. A demonstration project of a multi-component educational intervention to improve integrated post-fracture osteoporosis care in five rural communities in Ontario, Canada. Osteoporos Int 2009; 20: 265-274.
16. Briot K, Ravaud P, Dargent-Molina P, Zylberman M, Liu-Leage S, Roux C,. Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience. Osteoporos Int 2008; 20: 625-630.
17. Kuo I, Ong C, Simmons L, Bliuc D, Eisman JA, Center JR,. Successful direct intervention for osteoporosis in patients with minimal trauma fractures. Osteoporos Int 2007; 18: 1633-1639. (Pubitemid 47620315)
18. Curry LC, Hogstel MO, Davis GC, Frable PJ,. Population based osteoporosis education for older women. Public Health Nurs 2002; 19: 460-469.
19. Lai P, Chua SS, Chew YY, Chan SP,. Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women. J Clin Pharm Ther, 2011; 36: 557-567.
20. Lai P, Chua SS, Chan SP,. Does the knowledge of osteoporosis in postmenopausal osteoporotic women improve with pharmacist intervention? 8th Malaysian Pharmaceutical Society Pharmacy Scientific Conference, 77 Abstract PPP6, 2008.
21. Lai P, Chua SS, Chan SP,. The impact of pharmaceutical care on the quality of life of postmenopausal osteoporotic women prescribed bisphosphonates. Mala J Pharm 2009; 1:Abstract PPCP-21.
22. Dupont WD, Plummer WD,. PS: power and sample size calculation. 2004. Available at: http://biostat.mc.vanderbilt.edu/twiki/bin/view/Main/ PowerSampleSize, (updated 12 June; accessed 30 June 2007).
23. Schousboe JT, DeBold RC, Kuno LS, Weiss TW, Chen YT, Abbott TA,. Education and phone follow-up in postmenopausal women at risk for osteoporosis-Effects on calcium intake, exercise frequency, and medication use. Dis Manage Heal Outcomes 2005; 13: 395-404. (Pubitemid 41783777)
24. Abramson JH, Abramson ZH,. Survey methods in community medicine. ed. 5th edn. Edinburgh: Churchill Livingstone, 1999.
25. Foppe van Mil JW,. Classification for drug related problems (version 6.2). Pharmaceutical Care Network Europe Foundation, 2010 (updated 14 January 2010; cited 2010 29 Nov).
26. Sewerynek E, Dabrowska K, Skowronska-Jozwiak E, Zygmunt A, Lewinski A,. Compliance with alendronate 10 treatment in elderly women with postmenopausal osteoporosis. Endocrinol Pol 2009; 60: 76-81.
27. Clowes JA, Peel NFA, Eastell R,. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2004; 89: 1117-1123. (Pubitemid 38368399)
28. Papaioannou A, Kennedy C, Dolovich L, Lau E, Adachi J,. Patient adherence to osteoporosis medications: problems, consequences and management strategies [Review]. Drugs Aging 2007; 24: 37-55. (Pubitemid 46148080)
29. Lappe J,. Nonadherence to osteoporosis medications: a critical problem. Clin Rev Bone Mineral Metabol 2006; 4: 25-32. (Pubitemid 43780271)
30. Weycker D, Macarios D, Edelsberg J, Oster G,. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 2006; 17: 1645-1652. (Pubitemid 44477625)
31. Quek D,. Countering patients' irrational fear of side effects. 1997 Available at: http://www.vadscorner.com/editorial0597.html (accessed 15 September).
32. Wilson S, Wahler R, Brown J, Doloresco F, Monte SV,. Impact of pharmacist intervention on clinical outcomes in the palliative care setting. Am J Hosp Palliat Care 2011; 28: 316-320.
33. Von Muenster S, Carter B, Weber C, Ernst M, Milchak J, Steffensmeier J, Xu Y,. Description of pharmacist interventions during physician-pharmacist co-management of hypertension. Pharm World Sci 2008; 30: 128-135. (Pubitemid 350172660)
34. Roberts MS, Stokes JA, King MA, et al. Outcomes of a randomized controlled trial of a clinical pharmacy intervention in 52 nursing homes. Br J Clin Pharmacol 2001; 51: 257-265. (Pubitemid 32396417)
35. Murray MJ, LeBlanc CH,. Clinic follow-up from the emergency department: do patients show up? Ann Emerg Med 1996; 27: 56-58. (Pubitemid 26021322)
36. Roerholt C, Eiken P, Abrahamsen B,. Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence. Osteoporos Int 2009; 20: 299-307.
37. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH,. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis: the Alendronate Phase III Osteoporosis Treatment Study group. N Engl J Med 1995; 333: 1437-1443.